[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-exacerbation-of-idiopathic-pulmonary-fibrosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-exacerbation-of-idiopathic-pulmonary-fibrosis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100615983","phase-3-intravenous-immunoglobulin-for-the-treatment-of-acute-exacerbations-of-idiopathic-pulmonary-fibrosis-100615983",false,"NCT07299695","Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis","A Prospective, Multicenter, Randomized, Open-Label Clinical Trial Evaluating the Efficacy of Intravenous Immunoglobulin in Patients Hospitalized for Acute Exacerbations of Idiopathic Pulmonary Fibrosis.","MERCURION-IPF","Inclusion Criteria:\n\n1. Patients ≥ 18 years of age\n2. Patients with IPF diagnosis that fulfils ATS\u002FERS Consensus Criteria.\n3. Patients hospitalised with a definite or suspected AE-IPF diagnosis, as defined by the international working group criteria and as ascertained by the responsible Primary Investigator.\n\n   The criteria of IPF-AE are as follows:\n   * Previous or concurrent diagnosis of IPF\n   * Acute worsening or development of dyspnoea typically \\\u003C 1 month duration\n   * Computed tomography with new bilateral ground-glass opacity and\u002For consolidation superimposed on a background pattern consistent with usual interstitial pneumonia pattern\n   * Deterioration not fully explained by cardiac failure or fluid overload Patients who fail to meet all 4 criteria due to missing computed tomography should be considered as having \"suspected Acute Exacerbation\".\n\n   A) If the diagnosis of IPF is not previously established, this criterion can be met by the presence of radiologic and\u002For histopathologic changes consistent with usual interstitial pneumonia pattern on the current evaluation.\n\n   B) If no previous computed tomography is available, the qualifier \"new\" can be dropped from the third AE-IPF criterion.\n4. Patient able to understand and sign a written informed consent form. In case of incapacity of the patient, the written informed consent form will be signed by the patients' legally authorized representative.\n\nExclusion Criteria:\n\n1. Patients with acute worsening due to uncontrolled heart failure or pulmonary embolism.\n2. Patients with known hypersensitivity to corticosteroids, IVIG or any component of the study treatment.\n3. Patients with known IgA deficiency (IgA level \\\u003C7 mg\u002FdL)- to preclude IVIG reactions.\n4. Patients without a definite diagnosis of IPF or AE-IPF based on clinical, radiological, laboratory evaluation, and multidisciplinary discussion.\n5. Patients with active malignancy or currently receiving cancer treatment, except for basal cell or squamous cell skin cancer or low-risk prostate cancer (T1 or T2a stage with PSA \\\u003C10 ng\u002FdL). These criteria are aligned with current guidelines.\n6. Patients that have received treatment for \\>14 days within the preceding month with \\>20mg daily prednisone (or equivalent) or any treatment during the last month with immunosuppressants (e.g., cyclophosphamide, mycophenolate etc.) according to already published therapeutic protocols or \\> 1 mg\u002Fkg\u002Fd from more than 7 days in the last 15 days.\n7. Patients participating to another interventional clinical trial.\n8. Patients with documented pregnancy or lactation.\n9. Patients under tutorship or curatorship.\n10. Patients deprived of liberty or under court protection.\n11. Patients who refuse to participate or decline to provide written informed consent.","ALL","18 Years",{"count":20,"type":21},196,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) are sudden and severe worsening episodes that can be life-threatening. Currently, no treatment has been proven to clearly improve outcomes during these events. Inflammation and immune system imbalance are thought to play an important role in causing AE-IPF. Early clinical experience suggests that intravenous immunoglobulin (IVIG) can be beneficial for patients suffering from AE-IPF. This clinical trial aims to determine whether adding IVIG to usual treatment can improve outcomes for patients hospitalized with AE-IPF.",[27,28],"Idiopathic Pulmonary Fibrosis","Acute Exacerbation of Idiopathic Pulmonary Fibrosis",[30,27,31,28],"Acute Exacerbations of Idiopathic Pulmonary Fibrosis","Intravenous Immunoglobulin","RECRUITING","2026-03-12",{"date":35,"type":36},"2026-03-16","ACTUAL",{"date":38,"type":36},"2026-01-25",{"date":40,"type":21},"2028-12",{"name":42,"class":43},"Argyrios Tzouvelekis","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100491120","phase-3-glucocorticoids-versus-placebo-for-the-treatment-of-acute-exacerbation-of-idiopathic-pulmonary-fibrosis-100491120","NCT05674994","Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis","Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Randomized Controlled Trial","EXAFIP2","Inclusion Criteria:\n\n1. Patient is ≥ 18 years of age\n2. IPF or IPF (likely) diagnosis defined on 2018 international recommendations\n3. Definite or suspected Acute Exacerbation defined by the international working group criteria after exclusion of alternative diagnoses of acute worsening\n\n   \\*The criteria of IPF-AE are as follows:\n   * Previous or concurrent diagnosis of IPF (a)\n   * Acute worsening or development of dyspnea typically \\\u003C 1-month duration\n   * Computed tomography with new bilateral ground-glass opacity and\u002For consolidation superimposed on a background pattern consistent with usual interstitial pneumonia pattern (b)\n   * Deterioration not fully explained by cardiac failure or fluid overload Patients who fail to meet all 4 criteria due to missing computed tomography should be considered as having \"suspected Acute Exacerbation\".\n\n     1. If the diagnosis of IPF is not previously established, this criterion can be met by the presence of radiologic and\u002For histopathologic changes consistent with usual interstitial pneumonia pattern on the current evaluation.\n     2. If no previous computed tomography is available, the qualifier \"new\" can be dropped from the third criterion.\n4. For women of childbearing age: efficient contraception for the duration of the study\\*\n\n   \\*Effective contraception is defined as any contraceptive method that is used consistently and appropriately and has a low failure rate (i.e., less than 1% per year)\n5. Affiliation to the social security\n6. Patient able to understand and sign a written informed consent form or in case of incapacity of the patient to a relative whom understand and sign a written informed consent form\n\nExclusion Criteria:\n\n1. Identified etiology for acute worsening (i.e.: infectious disease)\n2. Known hypersensitivity to glucocorticoids or to any component of the study treatment\n3. Patient requiring mechanical ventilation or already on mechanical ventilation\n4. Active bacterial, viral, fungal or parasitic infection. On swab collected, only positive for SARS-CoV-2, Influenzae A, Influenzae B and Respiratory Syncytial Virus (RSV) result, are considered active viral infection. The others viruses (i.e. Rhinovirus, Adenovirus…) are not considered to be responsible of pneumonia.\n5. Active cancer\n6. Patient on a lung transplantation waiting list\n7. Treatment with glucocorticoids \\> 1 mg\u002Fkg\u002Fd from more than 7 days in the last 15 days\n8. Patient participating to another interventional clinical trial\n9. Documented pregnancy or lactation\n10. Patient under tutorship or curatorship\n11. Patient deprived of liberty\n12. Patient under court protection",{"count":54,"type":21},110,[24],"Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is associated with a poor prognosis, with a 3-month mortality rate of over 50%. To date, no treatment has been proven to be effective in AI-FPI. The interest of glucocorticoids is controversial and needs to be confirmed. This confirmation is mandatory to validate the improvement of the prognosis of EA-IPF under this treatment but also to search for unsuspected deleterious effects as it has been shown with immunosuppressants in stable idiopathic pulmonary fibrosis.",[28],"2026-02-26",{"date":60,"type":36},"2026-03-02",{"date":62,"type":36},"2023-10-26",{"date":64,"type":21},"2026-12-31",{"name":66,"class":43},"Fondation Hôpital Saint-Joseph",29]